Akums Drugs and Pharmaceuticals reports a robust start to FY27, with a 13.9% rise in quarterly revenue and a strong focus on expanding its contract development and manufacturing operations.
Akums Drugs and Pharmaceuticals Ltd. began FY27 with a stronger quarterly showing, as the Indian contract development and manufacturing group lifted revenue, margins and profit in the three months to June 30, according to a company statement released in New Delhi.
The company reported operating revenue of ₹1,167 crore for the quarter, up 13.9% from ₹1,024 crore a year earlier, while earnings before interest, tax, depreciation and amortisation rose 35.4% to ₹175 crore. EBITDA margin improved to 15% from 12.6%, and net profit climbed to ₹101 crore from ₹65 crore in the same period last year. Business Standard reported that Akums had already closed FY26 with revenue of ₹1,157.87 crore in the March quarter, suggesting the latest performance extends a recovery in momentum.
The CDMO division remained the main engine of growth. Revenue from that segment increased to ₹964 crore from ₹813 crore a year earlier, while CDMO EBITDA rose 36.8% to ₹163 crore. The company said volume growth and better realisations for active pharmaceutical ingredients supported the improvement. LiveMint reported that Akums’ comparable quarter a year earlier had been far more modest, with total revenue of ₹1,024.03 crore and net income of ₹63.48 crore, underlining how sharply the latest results improved.
Managing director Sanjeev Jain said the new fiscal year had started on a “strong and encouraging note” and described client demand as healthy. Managing director Sandeep Jain said the company was focused on strengthening its CDMO position, expanding higher-value capabilities and maintaining operational discipline. Separate reporting from Sahi.com said Akums is also preparing about ₹300 crore of capital spending in FY27, aimed at expanding oral solid dosage facilities and supporting further growth in its manufacturing business.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
